Skip to main content
News

The Changing Arena of US Patent Disputes: Why Ex Parte Reexamination Requests Have Surged by 162.8%

By September 2, 2026October 27th, 2026No Comments

1. Samsung Display’s Strategic Choice

On August 25 and 27, 2026, Samsung Display filed petitions for ex parte reexamination of two patents with the United States Patent and Trademark Office (USPTO). These petitions target patents that Neolayer—a Non-Practicing Entity (NPE)—asserted against Samsung Electronics in a patent infringement lawsuit filed in the U.S. District Court for the Eastern District of Texas in December 2023, seeking to invalidate the claims. The key takeaway from this action is Samsung Display’s deliberate selection of reexamination as its primary defensive tool.

For nearly a decade, Inter Partes Review (IPR) served as the primary defense mechanism for operating companies facing patent infringement claims. However, according to recent data, ex parte reexamination filings at the USPTO surged by 162.8%, increasing from 226 petitions in the first half of 2025 to 594 in the first half of 2026. Conversely, IPR petitions dropped sharply from 698 to 174 during the same period, with the second quarter of 2026 recording a quarterly all-time low of just 57 IPR filings since the system’s full implementation. Currently, reexamination accounts for 74.7% of all invalidation proceedings at the USPTO (comprising IPR, PGR, and reexamination)—almost an exact reversal of the 72.9% market share previously held by IPR just one year ago. [1, 2]

2. Overview of the Two Administrative Procedures

When served with an allegation of patent infringement in the United States, an accused party generally has two primary avenues of defense: litigating non-infringement and invalidity directly before the federal courts, or petitioning the USPTO to declare that the patent should not have been granted initially. The primary administrative mechanisms for challenging patent validity before the USPTO are:

  1. Inter Partes Review (IPR): An adversarial, trial-like proceeding conducted before the Patent Trial and Appeal Board (PTAB) where both the petitioner and the patent owner actively participate, submitting evidence and legal arguments throughout the process.

  2. Ex Parte Reexamination: An administrative procedure requesting the USPTO to reexamine an issued patent. Once the petitioner submits the initial request, it is excluded from further participation, and subsequent proceedings occur solely between the examining officer and the patent owner.

 

3. Factors Driving the Decline of IPR

The primary catalyst behind the shift away from IPR is the heightened threshold for institution decisions. Grounds for discretionary denial have expanded significantly, taking into account parallel court litigation, serial or redundant petitions, and the “settled expectations” of patent owners. [3] Furthermore, on November 6, 2025, the U.S. Court of Appeals for the Federal Circuit denied a petition for writ of mandamus, reinforcing that institution decisions are final and non-appealable pursuant to 35 U.S.C. § 314(d) (In re Motorola Solutions, Inc., No. 2025-134 (Fed. Cir. Nov. 6, 2025)). [3] This decision further restricted available avenues for judicial review.

Consequently, the IPR institution rate plummeted from 81.8% in January 2025 to 19.4% by August 2025, while monthly petition volume declined from 131 in January 2025 to just 22 in June 2026.

Moreover, a guidance memorandum issued by USPTO Director Squires on March 11, 2026, introduced three additional discretionary factors for evaluating IPR and PGR institution petitions: [4]

  • The extent to which the accused product in parallel litigation is manufactured in the United States or involves domestic manufacturing investments.

  • The extent to which the patent owner’s competing commercial products are manufactured within the United States.

  • Whether the petitioner is a small business entity sued under the subject patent.

Under these updated guidelines, foreign entities lacking a substantial manufacturing presence in the United States face a heightened risk of discretionary denial, regardless of the substantive merits of their invalidity arguments.

4. Comparative Analysis: Benefits and Risks of Reexamination

Advantages

Unlike IPR, ex parte reexamination is not subject to discretionary denial frameworks. Once a Substantial New Question of patentability (SNQ) is established, the USPTO is statutorily obligated to order reexamination pursuant to 35 U.S.C. §§ 303, 304, without considering domestic manufacturing criteria. Additionally, the strict one-year statutory filing bar applicable to IPR (35 U.S.C. § 315(b)) does not apply to reexamination, allowing petitions to be filed even after district court litigation has advanced significantly. Furthermore, petitioners can remain anonymous, and the associated procedural costs are substantially lower.

Disadvantages & Risks

Because the petitioner is excluded from the proceeding following the initial filing, the entirety of the legal and technical argument must be exhaustively presented in the initial petition. Moreover, petitioners possess no statutory right of appeal against adverse final decisions (35 U.S.C. § 306). Crucially, patent owners are permitted to amend claims during reexamination, creating the risk that the patent owner may successfully narrow and strengthen the patent claims against the accused infringer.

5. Strategic Recommendations for Enterprises

For Accused Parties (Defensive Strategy)

Entities facing infringement allegations must carefully weigh the relative merits of IPR, reexamination, and district court invalidity defenses. Given the strict one-year time bar for IPR, if the filing window is narrow or the probability of institution is low, ex parte reexamination offers a viable alternative. Additionally, companies should proactively organize factual documentation regarding U.S. manufacturing footprint, domestic investments, and employment to ensure immediate submission when contesting discretionary denials.

For U.S. Patent Holders (Enforcement Strategy)

Because reexamination lacks strict time limitations, permits petitioner anonymity, and involves lower costs, U.S. patents held by Korean enterprises are increasingly vulnerable to third-party administrative challenges. Patent owners are advised to establish robust internal monitoring procedures for key commercial assets to utilize pre-order response mechanisms (e.g., submitting preliminary statements within 30 days of receiving notice of a reexamination petition) where appropriate.

This publication provides general information regarding U.S. patent practice trends and does not constitute formal legal advice. Specific legal matters require individualized counsel.

Footnotes & Citations:

  • [1] ZDNet Korea, “Samsung Display Counterattacks Neolayer’s OLED Patents… Petitions USPTO for Reexamination” (Aug. 30, 2026).

  • [2] Unified Patents, Patent Dispute Report: First Half 2026 (July 9, 2026).

  • [3] Memorandum from Coke Morgan Stewart, Acting Dir., USPTO, Interim Processes for PTAB Workload Management (Mar. 26, 2025); In re Motorola Solutions, Inc., No. 2025-134 (Fed. Cir. Nov. 6, 2025) (precedential).

  • [4] Memorandum from John A. Squires, Dir., USPTO, Additional Discretionary Institution Considerations — U.S. Manufacturing and Small Business Use of AIA Proceedings (Mar. 11, 2026).

ACI LAW GROUP
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.